NEW YORK (GenomeWeb News) – Trovagene today announced it has granted to Genoptix a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia.
Genoptix, a Novartis company, will pay Trovagene upfront and royalty payments. Further terms of the deal were not disclosed.
Trovagene holds the exclusive worldwide license to the patent around NPM1 and has granted sublicenses to offer mutation analysis of the protein as a laboratory service for the diagnosis and monitoring of patients with AML to Quest Diagnostics, Laboratory Corporation of America, Münchner Leukamielabor in Germany, Skyline Labs in the Netherlands, and others.
NPM1 mutation testing is recommended by the national Comprehensive Cancer Network, which sets clinical treatment standards for a number of cancers, Trovagene said.
The San Diego-based molecular diagnostics firm also has deals to manufacture and sell NPM1 mutation kits to Asuragen and Ipsogen, which was acquired by Qiagen last year.